Sexcord/ stromal ovarian tumors epidemiology and demographics

Sexcord/ stromal ovarian tumors Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sexcord/ stromal ovarian tumors epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sexcord/ stromal ovarian tumors epidemiology and demographics
CDC on Sexcord/ stromal ovarian tumors epidemiology and demographics
Sexcord/ stromal ovarian tumors epidemiology and demographics in the news
Blogs on Sexcord/ stromal ovarian tumors epidemiology and demographics
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Sexcord/ stromal ovarian tumors epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Epidemiology and Demographics

Incidence

Ovarian sex cord-stromal tumors are very uncommon neoplasms that represent only 7% of all ovarian tumors

Ovarian cancer incidence exhibits wide geographic variation.Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. doi:10.20892/j.issn.2095-3941.2016.0084,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365187/

Prevalence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
• The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

• In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
• The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

The age at presentation varies depending on the subtypes of sexcord-stromal ovarian tumors:

Fibromas:

• Although they can present at any age, the mean age of occurrence is in the late forties

Thecomas:

• They are more likely to occur in postmenopausal women

Sclerosing stromal tumor(SSTs):

• SSTs are more likely to occur in young women
• Approximately 80% of the reported cases are under 30 years of age
• A few cases have been reported in premenarchal girls, although SSTs most commonly occur after menarche

Steroid cell tumors:

• The average age of presentation is 43 years

Adult and juvenile granulosa cell tumors:

• The incidence of adult granulosa cell tumors peaks in early postmenopausal women
• The juvenile form occurs predominantly in children and young women (<30 years)

Race

• Racial predilection do exist for sexcord-stromal ovarian tumors

Within the United States, racial differences in incidence and mortality mimic the observed international variation with Rates highest among Whites, intermediate for Hispanics, and lowest among Blacks, and Asian

Region

• The majority of [disease name] cases are reported in [geographical region].

• [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].